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HIV infection has been considered as one of the major global
public health threats of the last century, increasing several
times the mortality rate in comparison to the cholera epi-
demic that swept London in the nineteenth century. Unlike
the contamination caused by cholera bacillus, prevention of
HIV infection requires other interventions than basic sanita-
tion, and the antiretroviral agents currently remain the touch-
stone to transform the disease from subacute into a chronic
condition. The introduction of highly active antiretroviral
therapy (HAART) in the treatment of HIV-infected patients,
in 1990s, has allowed better health status and greater longevity
among people living with HIV, associated with a reduction in
the viral transmission rate. For a while, it has been believed
that universal access to HAART and the progressive increase
in the efficiency of the prevention methods could save future
generations [1]. However, it requires an enormous effort to
expand HIV testing, maintenance of sustained treatment,
and implementation of prevention programs. Nevertheless,
HAART is not free of adverse effects.
With the significant reduction of the mortality and mor-
bidity associated with HIV induced immunodeficiency in
patients using HAART, the HIV infection is behaving as
a long-term sickness [2]. HIV infection and its treatment
have been associated with abnormal metabolic profile [3];
increased prevalence of noncommunicable diseases [4, 5] and
mortality rate of AIDS-related have shifted to non-AIDS-
related conditions [6, 7]. In the pre-HAART era, mortality
from cardiovascular disease in infected persons occurred
almost two decades earlier than in the general population.
After the introduction of HAART, this difference went on to
about nine years [8]. Even though the HIV-infected popu-
lation is getting older, most still ar less than 50 years old and,
in the United States, only half of the population will be 50
years in 2015 [9]. Therefore, the long-term management of
patients with HIV infection has to be expanded to diagnosis,
treatment, and prevention of cardiovascular risk factors and
coronary heart disease. Even so, most current guidelines for
the treatment of HIV infection are still focused only on
antiretroviral treatment and do not take into account the
treatment and prevention of comorbidities not related to
AIDS [10–12]. However, bringing the paradigm of cardiovas-
cular disease prevention for the scenario of HIV infection
requires detection of the prevalence of cardiovascular risk
factors and coronary heart disease in HIV-infected patients.
In this edition of this journal, a portrait of the Brazil-
ian scenario of cardiovascular disease among HIV-infected
patients was presented. Brazil is a country that has provided
free access to HIV treatment for the entire population of infe-
cted people in the last two decades, and the use of
HAART had a great impact on the costs of health care and
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the demand for the public health system. D. V. Araújo et al.
showed that, in the last five years, the number of HIV/AIDS
cases increased approximately by 40%, among patients under
50-years of age, yet the hospital admissions due to AIDS
remained stable. Conversely, there was a marked increase in
the hospitalizations due to acute myocardial infarction. R.
K. Lazzaretti et al. provided data on genetic basis for under-
standing the complexity of the dyslipidemia inHIV infection.
They detected that single nucleotide polymorphisms in six
candidate genes (APO B, APO A5, APO E, APO C3, SCAP,
and LDLR) were associated with dyslipidemia, showing that
genetic factors contribute to determining the lipid profile in
HIV-infected individuals on antiretroviral therapy.
Even so, there is a lack of robust evidence for prescribing
agents to reduce dyslipidemia in HIV-infected patients. The
new guidelines for cholesterol treatment highlighted the lack
of randomized clinical trials on the potential benefits of statin
therapy to reduce the risk of atherosclerotic cardiovascular
disease inHIV-infected patients exceeding the risk of adverse
events or drug interactions [13].
Another approach, previously described for the general
population [14, 15], was to determine whether the association
between consumption of alcoholic beverages and hyper-
tension was modified by race in HIV-infected individuals.
Among lifestyle characteristics, the consumption of large
amounts of alcohol was independently associatedwith hyper-
tension in white and nonwhite HIV-infected individuals. M.
L. R. Ikeda et al. showed that there was an association of
blood pressure with the frequency of consumption among
the whites, while for nonwhite participants the amount of
alcohol consumed was more important than the pattern of
consumption in raising blood pressure. Although some of
lifestyle characteristics are not modifiable, alcohol consump-
tion is suitable for intervention.
In an attempt to compare some tools available to assess the
overall cardiovascular risk profile of HIV-infected patients,
M. W. Nery et al. calculated the traditional Framingham risk
score, the Prospective Cardiovascular Münster (PROCAM)
score; both originally developed for non-HIV-infected pop-
ulation; and the Data Collection on Adverse Effects on Anti-
HIVDrugs (DAD) score, validated onHIV-infected patients.
They found that the proportion of patients classified as being
at moderate risk or higher was larger for the Framingham
than for the PROCAM score. While these results have
clinical follow-up and management implications, there was
no comparisonwith data collected for the incidence of events.
The use of Framingham score seems to have the advantage
of allowing the comparison with other studies conducted in
non-HIV-infected population [16]. Finally, a pooled analysis
carried out in three cities of the Northeast, Midwest, and
Southern Brazil showed that, irrespective of HIV status
or treatment, classically risk-associated conditions, such as
hypertension and diabetes, persist as the most relevant risk
factors for cardiovascular disease.Moreover, these conditions
were present at a younger age in the studied population.
Of note is also the high prevalence of moderate and high
risk according to the Framingham risk score among women.
In this group, the diagnosis of cardiovascular disease and
ischemic heart disease frequently occurs later than in men.
This study reminds us that it is never too early to approach
these problems and emphasize primary prevention of car-
diovascular disease, even among populations with chronic
conditions such as the HIV infection. We believe that the
spectrum of cardiovascular manifestations among patients
infected by HIV, pictured in this edition, allows the design
and implementation of initiatives aimed at controlling and
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